Neoadjuvant Chemoradiotherapy improves oncological results in resectable and borderline resectable Pancreatic Carcinomas, but not Overall Survival in resectable ones Results of the Dutch PREOPANC Study

被引：0
作者：
Hermann, Robert Michael [1 ]
Christiansen, Hans [2 ]
机构：
[1] Zentrum Strahlentherapie, Mozartstr 30, D-26655 Westerstede, Germany
[2] Hannover Med Sch, Klin Strahlentherapie & Spezielle Onkol, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2021年 / 197卷 / 01期
关键词：
GEMCITABINE;
D O I：
10.1007/s00066-020-01717-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：85 / 88
页数：4
相关论文
共 5 条
  • [1] FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
    Conroy, T.
    Hammel, P.
    Hebbar, M.
    Ben Abdelghani, M.
    Wei, A. C.
    Raoul, J. -L.
    Chone, L.
    Francois, E.
    Artru, P.
    Biagi, J. J.
    Lecomte, T.
    Assenat, E.
    Faroux, R.
    Ychou, M.
    Volet, J.
    Sauvanet, A.
    Breysacher, G.
    Di Fiore, F.
    Cripps, C.
    Kavan, P.
    Texereau, P.
    Bouhier-Leporrier, K.
    Khemissa-Akouz, F.
    Legoux, J. -L.
    Juzyna, B.
    Gourgou, S.
    O'Callaghan, C. J.
    Jouffroy-Zeller, C.
    Rat, P.
    Malka, D.
    Castan, F.
    Bachet, J. -B.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (25) : 2395 - 2406
  • [2] R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial
    Fietkau, R.
    Gruetzmann, R.
    Wittel, U. A.
    Croner, R. S.
    Jacobasch, L.
    Neumann, U. P.
    Reinacher-Schick, A.
    Imhoff, D.
    Boeck, S.
    Keilholz, L.
    Oettle, H.
    Hohenberger, W. M.
    Golcher, H.
    Bechstein, W. O.
    Uhl, W.
    Pirkl, A.
    Adler, W.
    Semrau, S.
    Rutzner, S.
    Ghadimi, M.
    Lubgan, D.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (01) : 8 - 18
  • [3] Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial
    Jang, Jin-Young
    Han, Youngmin
    Lee, Hongeun
    Kim, Sun-Whe
    Kwon, Wooil
    Lee, Kyung-Hun
    Oh, Do-Youn
    Chie, Eui Kyu
    Lee, Jeong Min
    Heo, Jin Seok
    Park, Joon Oh
    Lim, Do Hoon
    Kim, Seong Hyun
    Park, Sang Jae
    Lee, Woo Jin
    Koh, Young Hwan
    Park, Joon Seong
    Yoon, Dong Sup
    Lee, Lk Jae
    Choi, Seong Ho
    [J]. ANNALS OF SURGERY, 2018, 268 (02) : 215 - 222
  • [4] Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma A Phase 2 Clinical Trial
    Murphy, Janet E.
    Wo, Jennifer Y.
    Ryan, David P.
    Jiang, Wenqing
    Yeap, Beow Y.
    Drapek, Lorraine C.
    Blaszkowsky, Lawrence S.
    Kwak, Eunice L.
    Allen, Jill N.
    Clark, Jeffrey W.
    Faris, Jason E.
    Zhu, Andrew X.
    Goyal, Lipika
    Lillemoe, Keith D.
    DeLaney, Thomas F.
    Fernandez-del Castillo, Carlos
    Ferrone, Cristina R.
    Hong, Theodore S.
    [J]. JAMA ONCOLOGY, 2018, 4 (07) : 963 - 969
  • [5] Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer
    Versteijne, E.
    Vogel, J. A.
    Besselink, M. G.
    Busch, O. R. C.
    Wilmink, J. W.
    Daams, J. G.
    van Eijck, C. H. J.
    Koerkamp, B. Groot
    Rasch, C. R. N.
    van Tienhoven, G.
    [J]. BRITISH JOURNAL OF SURGERY, 2018, 105 (08) : 946 - 958
1